



Queensland
Government

Metro North
Hospital and Health Service

Dear GP,

As you have most likely have encountered, semaglutide (Ozempic) and dulaglutide (Trulicity) are in very limited supply.

The TGA has released a joint position statement, advising Ozempic will be **unavailable** in Australia until the end of March 2023. Trulicity is expected to have limited availability. Exenatide (Byetta) will be discontinued once stock is depleted, which is anticipated to occur 1st December 2022.

We have received correspondence from the Australian Diabetes Society (ADS) on the 6th November 2022, which outlines alternative options to GLP-1RA therapy (please see attached).

As always, we thank our general practitioner colleagues for assisting our joint patients with diabetes, particularly at challenging times like this. Your support and expertise are invaluable.

Please refer to the ADS email which suggests alternatives

Regards,

Dr Melissa Clarke / Dr Rakesh Malhotra

Endocrinologist

Provider No.: 408350JF / 4597045J